Table 2.
Outcome | Total | Q1 (NLR<3.68) | Q2 (3.68≤NLR<6.89) | Q3 (6.89≤NLR<12.14) | Q4 (12.14≤NLR) | P |
---|---|---|---|---|---|---|
N=594 | (n=148) | (n=149) | (n=149) | (n=148) | ||
30-day follow-up | ||||||
mRS≥3(3–6) | 387(65.2) | 85(57.4) | 82(55.0) | 99(66.4) | 121(81.8) | <0.001 |
Disabled (3–5) | 267(56.3) | 59(48.4) | 64(48.9) | 69(58.0) | 75(73.5) | <0.001 |
Death | 120(20.2) | 26(17.6) | 18(12.1) | 30(20.1) | 46(31.1) | <0.001 |
3-month follow-up | ||||||
mRS≥3(3–6) | 348(58.6) | 73(49.3) | 72(48.3) | 87(58.4) | 116(78.4) | <0.001 |
Disabled (3–5) | 221(47.3) | 46(38.0) | 53(40.8) | 54(46.6) | 68(68.0) | <0.001 |
Death | 127(21.4) | 27(18.2) | 19(12.8) | 33(22.2) | 48(32.4) | <0.001 |
1-year follow-up | ||||||
mRS≥3(3–6) | 304(51.2) | 66(44.6) | 55(36.9) | 78(52.4) | 105(71.0) | <0.001 |
Disabled (3–5) | 161(35.7) | 36(30.5) | 28(23.0) | 43(37.7) | 54(55.7) | <0.001 |
Death | 143(24.1) | 30(20.3) | 27(18.1) | 35(23.5) | 51(34.5) | 0.005 |
Note: Values are number (%).
Abbreviations: NLR, neutrophil-to-lymphocyte ratio; mRS, modified Rankin Scale.